Figure 1.

Comparison of established (Freelite) and novel (Siemens) serum free light chain assays in patients with multiple myeloma and acute kidney injury. The new serum FLC assays did not identify nephrotoxic levels of monoclonal FLCs in 18% of patients studied (A), largely this can be explained by the poor performance of the lambda assay (B). In comparison the correlation of the kappa assays was reasonable (C).

Hutchison et al. BMC Clinical Pathology 2012 12:12   doi:10.1186/1472-6890-12-12
Download authors' original image